A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Although this was a negative study, I think the data shown here contribute to our knowledge of IO treatments in urothelial cancer,” said Michiel Van der Heijden, MD, PhD.

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...

Discover the latest updates to the EAU guidelines for muscle-invasive and metastatic bladder cancer in 2025. Learn more.

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...

The majority of patients with the most common advanced or metastatic cancers in the United States do not undergo ...

The term 'Cancer' makes a person freeze the moment they hear it for the first time, and one such type of cancer is bladder cancer. While this may look scary, its timely diagnosis can help in managing ...

Carlsbad, California Tuesday, July 1, 2025, 16:00 Hrs [IST] ...